Skip to main content

Table 1 Multifunctional (IFNg and TNFα) T cell responses to MAGE-A3

From: A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes

 

% of CD4+ T cells

% of CD8+ T cells

 

(90% CI)

(90% CI)

 

SIN

PBMC

Either

SIN

PBMC

Either

Arm A

31%

31%

54%

0%

8%

8%

 

(11, 58)

(11, 58)

(29, 78)

(0, 21)

(0, 32)

(0, 32)

Arm B

64%

50%

75%

18%

25%

33%

 

(35, 86)

(25, 75)

(47, 93)

(3, 47)

(7, 53)

(12, 61)

Total

46%

40%

64%

8%

16%

20%

 

(28, 64)

(24, 58)

(46, 80)

(2, 24)

(6, 33)

(8, 38)